RANOLAZINE REFRACTORY ANGINA REGISTRY TRIAL: 1-YEAR RESULTS
نویسندگان
چکیده
منابع مشابه
CHALLENGE Trial 1 Year Feasibility Results-Letter.
We were delighted to read the recent report by Courneya and colleagues on the 1-year feasibility and fitness benefits of a structured exercise program among colon cancer survivors in the CHALLENGE Trial (1). These findings, and the expected 3-year follow-updata, are an important contribution to thenascent body of research examining the effectiveness of sustained exercise behavior change in canc...
متن کاملNonconventional therapeutic modalities in refractory angina pectoris
Abstract Despite sophisticated conventional medical treatment and the continued development and improvement of coronary revascularization modalities in recent years, a significant number of patients still suffer from refractory angina pectoris and cannot be successfully managed. Advances in therapeutic options have led to an increase in the average of life expectancy even in such ...
متن کاملAntianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial.
OBJECTIVES The purpose of this study was to determine if ranolazine improves angina in stable coronary patients with persisting symptoms despite maximum recommended dose of amlodipine. BACKGROUND Ranolazine is a unique antianginal agent that has been effective in stable angina, but it has not been studied in the setting of maximum recommended doses of conventional antianginal agents. METHOD...
متن کاملRefractory atrial fibrillation effectively treated with ranolazine.
Atrial fibrillation is the most common sustained cardiac arrhythmia which is often troublesome to manage. Currently, rhythm and rate control medications are the mainstays of therapy. In 2 amiodarone-refractory highly symptomatic patients, an innovative approach using ranolazine, which selectively acts on Na+ channels and delays atrial depolarization, was tried successfully.
متن کاملRefractory Unstable Angina
Background Patients with unstable angina despite intensive medical therapy, ie, refractory angina, are at high risk for developing thrombotic complications: myocardial infarction or coronary occlusion during percutaneous transluminal coronary angioplasty (PTCA). Chimeric 7E3 (c7E3) Fab is an antibody fragment that blocks the platelet glycoprotein (GP) Ib/IIIa receptor and potently inhibits plat...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of the American College of Cardiology
سال: 2011
ISSN: 0735-1097
DOI: 10.1016/s0735-1097(11)61050-4